Nodetrip (previously Xeristar)

RSS

duloxetine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Nodetrip has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 22/06/2021

Authorisation details

Product details
Name
Nodetrip (previously Xeristar)
Agency product number
EMEA/H/C/000573
Active substance
duloxetine
International non-proprietary name (INN) or common name
duloxetine
Therapeutic area (MeSH)
  • Anxiety Disorders
  • Depressive Disorder, Major
  • Diabetic Neuropathies
Anatomical therapeutic chemical (ATC) code
N06AX21
Publication details
Marketing-authorisation holder
Esteve Pharmaceuticals, S.A.
Revision
32
Date of issue of marketing authorisation valid throughout the European Union
17/12/2004
Contact address

Passeig de la Zona Franca, 109
08038 Barcelona
Spain

Product information

12/05/2021 Nodetrip (previously Xeristar) - EMEA/H/C/000573 - WITHDRAWAL

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Psychoanaleptics

Therapeutic indication

  • Treatment of major depressive disorder;
  • Treatment of diabetic peripheral neuropathic pain;
  • Treatment of generalised anxiety disorder;
  • Xeristar is indicated in adults.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating